Comparación de la eficacia terapéutica entre infliximab adalimumab y etanercept, en el tratamiento de artritis reumatoidea en el IESS de Loja

Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease, affects about 1% of the general population and causes progressive joint destruction, disability and decreased life expectancy. Compression of the etiology and pathogenesis of RA has allowed the development of new drug therapies in which the biological treatment, which allows the same remission and disease control is included. The present investigation seeks to make the comparison of therapeutic efficacy between infliximab, adalimumab, etanercept in the treatment of rheumatoid arthritis in the IEES of Loja. Using the Scientific Method and by collecting data through a structured survey and implementation of Score DAS28 to assess RA activity and also the first two controls at 3 months and the second at 6 months after the administered biological study. With this research concludes that: Infliximab is biological with better therapeutic efficacy since achieved the 75.00% of mild activity as Score DAS28 at six months, RA affects a 61.67% female, age affected with most often it is between 46 and 50 years at 41.67%. None of the studied biological achieving remission in RA according Score DAS-28. ESR values were determined at baseline, three and six months of the study observed values between 11-15 mm/h in 55.00% with infliximab at 6 months. The most frequent symptoms are joint pain and morning stiffness in 100.00% of the patients studied, six months after the biological treatment has 53.33% join pain and 25.00% stiffness. Keywords: Rheumatoid arthritis, DAS 28, Infliximab, Adalimumab, Etanercept

• Auteur principal: Amay Sánchez, Gabriela Natali (author)
• Format: bachelorThesis
• Langue: spa
• Publié: 2015
• Sujets: ARTRITIS REUMATOIDEA; TRATAMIETO FARMACOLÓGICO-REUMATISMO
• Accès en ligne: http://dspace.unl.edu.ec/jspui/handle/123456789/12799